L-Folinic acid

Phase 3Small molecule

IInstitut Cancerologie de l'Ouest

L-Folinic acid is one of 44 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerRecruiting

Metastatic Colorectal CancerPhase 3

Recruiting

Competition

Competitive Landscape

141 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

20 2

Opdivo

Bristol-Myers Squibb

Phase 3

13 3

Braftovi

Pfizer

Phase 3

11 4

Tecentriq

Roche

Phase 3

10 5

FOLFIRI

Amgen

Phase 3

36 6

Yervoy

Bristol-Myers Squibb

Phase 3

7 7

Folinic Acid

Roche

Phase 3

17 8

Lumakras

Amgen

Phase 3

1 9

FOLFOX

AstraZeneca

Phase 3

14 10

Trifluridine/tipiracil

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Metastatic Colorectal Cancer

NCT06509126

Clinical

Trials by Indication[1]

Peritoneal Metastases1 trial

Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers

Terminated·IInstitut Cancerologie de l'Ouest·Phase 1/2·NCT03294252·34 enrolled

Metastatic Colorectal Cancer1 trial

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

Recruiting·NNational Cancer Institute, Naples·Phase 3·NCT06509126·500 enrolled

Biliary Tract Cancer1 trial

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

Completed·TThe Christie NHS Foundation Trust·Phase 3·NCT01926236·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for L-Folinic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-Folinic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-Folinic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut Cancerologie de l'Ouest company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInstitut Cancerologie de l'Ouest

L-Folinic acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Peritoneal Metastases1 trial

Metastatic Colorectal Cancer1 trial

Biliary Tract Cancer1 trial

References

Drug Info

Quick Facts

Related News